Upcoming Changes in the US Specialty Pharmacies
The US health officials are forging ahead with plans to permit specialty pharmacies to manufacture certain peptides. Peptides are a type of injectable that have soared in popularity among the followers of the Health Secretary Robert F. Kennedy Jr. and other wellness influencers. This may offer a significant opportunity for specialty pharmacies seeking to expand their product offering.
The Peptides Interim Access Policy
The Department of Health and Human Services, headed by Kennedy, has submitted an interim access policy for peptides to the White House for review. This policy was forwarded to the Office of Management and Budget, responsible for reviewing federal rules and regulations that have potential economic impact.
Nevertheless, the officials from HHS have not yet provided any comments as of Thursday afternoon.
Understanding Peptides and their Uses
Peptides are responsible for triggering hormones inside the body. This is essential for growth, metabolism, and healing. Several drug companies have introduced them as medicines, including treatments for diabetes and weight loss.
However, the ones in question here have not gone through a rigorous vetting process and are not approved by the Food and Drug Administration. Despite this, they are widely used by Americans pursuing enhanced muscle growth, anti-aging effects, or improved energy levels. Most data on peptides come from animal studies.
Peptides and the Gray Market
Before joining the administration, Kennedy voiced that the FDA’s war on peptides would soon end. As the health secretary, he advocated that US compounding pharmacies must be allowed to sell peptides as Americans were turning to gray market peptides from China and other countries. These products are widely available for purchase via various online platforms like TikTok.
Details on the New Policy
The White House filing didn’t provide specific details on the new policy, but it’s rumored to allow pharmacies to temporarily compound popular peptides, including BPC-157, noted for muscle building and healing injuries. The policy seems to be a response to the Make America Healthy Again movement, with some of its most prominent figures selling peptide injections and supplements.
Risks Involved with Peptides
The FDA had earlier listed BPC-157 and over a dozen other injectable peptides as substances too risky for compounding by pharmacies. Risks include potential contamination, allergic reactions, and tumor growth. However, Kennedy directed the agency to reconsider the list of these chemicals, which have been largely promoted by wellness influencers and fitness celebrities.
What the New Policy Means for Compounding Pharmacies
The new policy forwarded to the White House would essentially assure compounding pharmacies that they will not be targeted for producing certain peptides. This approach allows the FDA to selectively avoid enforcing some of its regulations. However, adding the peptides to FDA’s safe drugs list for compounding would require a federal rulemaking process, which could take years and involves multiple rounds of public comment.
Response to the New Proposal
The proposal was quickly praised online by some Kennedy allies who sell peptides. Brigham Buhler, a wellness clinic operator who sells peptides through an online service, posted on X that this is about medical freedom.
Peptide Business and Telehealth Providers
The business of peptides has caught the attention of major telehealth providers, including Hims & Hers and Noom. Both companies announced plans to offer peptides to customers if the federal government eases access. Wall Street analysts estimate the market could be worth $2 to $3 billion.
—
Read More Health & Wellness News; US Lifestyle News